(NASDAQ: RPRX) Royalty Pharma's forecast annual revenue growth rate of 14.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.1%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.02%.
Royalty Pharma's revenue in 2024 is $2,238,561,000.On average, 2 Wall Street analysts forecast RPRX's revenue for 2024 to be $1,603,752,843,588, with the lowest RPRX revenue forecast at $1,565,028,751,993, and the highest RPRX revenue forecast at $1,642,476,935,182. On average, 2 Wall Street analysts forecast RPRX's revenue for 2025 to be $1,749,031,664,777, with the lowest RPRX revenue forecast at $1,710,444,983,755, and the highest RPRX revenue forecast at $1,787,618,345,799.
In 2026, RPRX is forecast to generate $1,866,650,932,631 in revenue, with the lowest revenue forecast at $1,866,650,932,631 and the highest revenue forecast at $1,866,650,932,631.